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Abstract
The enteric nervous system (ENS) regulates peristaltic movement of the gut, and abnormal ENS causes Hirschsprung’s
disease (HSCR) in newborns. HSCR is a congenital complex genetic disorder characterised by a lack of enteric ganglia along
a variable length of the intestine. The receptor tyrosine kinase gene (RET) is the major HSCR gene and its expression is
crucial for ENS development. We have previously reported that (i) HOXB5 transcription factor mediates RET expression, and
(ii) mouse with defective HOXB5 activity develop HSCR phenotype. In this study, we (i) elucidate the underlying mechanisms
that HOXB5 mediate RET expression, and (ii) examine the interactions between HOXB5 and other transcription factors
implicated in RET expression. We show that human HOXB5 binds to the promoter region 59 upstream of the binding site of
NKX2-1 and regulates RET expression. HOXB5 and NKX2-1 form a protein complex and mediate RET expression in a
synergistic manner. HSCR associated SNPs at the NKX2-1 binding site (-5G.A rs10900296; -1A.C rs10900297), which
reduce NKX2-1 binding, abolish the synergistic trans-activation of RET by HOXB5 and NKX2-1. In contrast to the synergistic
activation of RET with NKX2-1, HOXB5 cooperates in an additive manner with SOX10, PAX3 and PHOX2B in trans-activation
of RET promoter. Taken together, our data suggests that HOXB5 in coordination with other transcription factors mediates
RET expression. Therefore, defects in cis- or trans-regulation of RET by HOXB5 could lead to reduction of RET expression and
contribute to the manifestation of the HSCR phenotype.
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Introduction
In mammalian embryos, neural crest cells (NCC) migrate from
the neural tube, enter the foregut and colonize the gut, where they
differentiate into neurons and glia of the enteric nervous system
[1]. The enteric nervous system (ENS) comprises a network of
neuronal ganglia and glia within the gut wall, which controls gut
peristalsis. In human, abnormal ENS development results in
absence of ganglia at the caudal-most gut in newborns with
Hirschsprung disease (HSCR), and patients develop a life-
threatening condition of intestinal obstruction due to defective
peristalsis. HSCR is a complex oligogenic disease and a major
ENS developmental disorder affecting newborns with variable
incidence in different races, and is most often found in Asians (28
per 100,000 live births) [2].
The receptor tyrosine kinase gene RET encodes a receptor for
glial cell-line derived neurotrophic factor (GDNF) on NCC and is
crucial for ENS development [3–6]. RET is the major HSCR
gene, and loss-of-function mutations in RET account for up to
50% of familial and 7–35% of sporadic cases of HSCR [7–12].
Other genes implicated in HSCR that account for 7% of cases
encode proteins involved in signaling pathways such as the
endothelin 3/endothelin receptor B, and transcription factors
SOX10, PHOX2B, NKX2-1 (also known as TITF-1), which
govern ENS development [1,13,14]. Some of these transcription
factors, for example NKX2-1 and SOX10 bind to cis-regulatory
elements of the RET gene and regulate RET expression
[13,15,16]. Single nucleotide polymorphisms (SNPs) affecting the
binding and regulatory activities of NKX2-1 and SOX10 on RET
were found associated with a reduced expression level of RET in
patients and increasing risk of HSCR development [17,18]. These
data indicated that the manifestation of the HSCR phenotype may
result from the interaction between altered genes of these
signalling pathways, which may ultimately result in an altered
expression of RET, and consequently in the HSCR phenotype.
In human and mouse embryonic guts, Homeobox (HOX) gene
HOXB5 is expressed in both migrating NCC and the gut
mesenchyme, and the expression pattern of HOXB5 is associated
with the migration and differentiation of NCC, suggesting a unique
role of HOXB5 in ENS and gut musculature development [19–22].
To investigate Hoxb5 function in ENS development and to
circumvent the problem of functional redundancy, we generated
transgenic mice that can be induced by Cre to express a chimeric
protein (enb5) in NCC. In this, the DNA-binding homeodomain of
Hoxb5 is linked to the repressor domain of the Drosophila engrailed
protein. This chimeric enb5 repressor competes with wild-type
Hoxb5 for binding to target genes and inhibits transcription,
thereby blocking the developmental pathways that normally require
Hoxb5. We showed that the Hoxb5 trans-activated Ret expression,
and that perturbation of Hoxb5 function caused down-regulation of
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Ret in NCC resulting in defective NCC migration in the developing
gut and HSCR phenotype in enb5/Cre transgenic mice [23]. Our
data indicate Ret is a downstream target of Hoxb5 whose
perturbation causes reduced Ret expression, impairs NCC
migration and leads to ENS phenotypes. In addition, our case-
control study suggests HOXB locus may affect the penetrance of the
HSCR [24]. Therefore, it is crucial to delineate the underlying
mechanisms HOXB5 regulate RET expression to unravel the roles
of HOXB5 in the etiology of HSCR.
In this study, we show that human HOXB5 physically binds
with the promoter of the human RET gene and regulates RET
expression. HOXB5 and NKX2-1 form protein complex and
work synergistically in the activation of RET expression. The
synergistic interaction of HOXB5 and NKX2-1 in the activation
of RET expression is compromised by promoter SNPs, that disrupt
the NKX2-1 binding to the RET promoter.
Results
HOXB5 trans-activates RET promoter
Our group has previously reported that Hoxb5 induces transcrip-
tion of Ret in mice [23]. To study if HOXB5 protein trans-activates
human RET promoter, we examined the transcriptional activity of
HOXB5 on a luciferase reporter construct consisting of 3.7kb human
RET promoter sequence 59 upstream of luciferase gene. SK-N-SH
neuroblastoma cell was shown to express RET, NKX2-1, PHOX2B,
but not SOX10, PAX3 [25]. In addition, SK-N-SH cell also did not
express HOXB5 (our unpublished data). Therefore, SK-N-SH cell
was chosen to examine the regulatory role of HOXB5 on RET gene.
HOXB5 displayed a 7-fold induction of transcription from human
RET promoter, as compared to empty vector control pRC/CMV
(Figure 1). In silico analysis identified HOX consensus binding motif in
the promoter of human RET gene, suggesting that HOX may
regulate RET expression by binding to the promoter (Figure 2A, B).
To delineate the cis-element in the promoter responsible for HOXB5
induction, 59 deletion reporter constructs spanning 21205 to +196
(Del.D), and 2177 to +196 (minimal promoter construct) were
generated and tested for HOXB5 induction. HOXB5 induced
luciferase activity from Del.D comparable to that from the full-length
promoter. In contrast, luciferase activity from the minimal promoter
construct was significantly lower than those from the full-length and
Del.D reporter constructs (Figure 2C), which suggested that the
region spanning from21205 and 2177 was important for HOXB5
induction.
Overlapping PCR fragments spanning the promoter region
(21205 to 2177) were tested for HOXB5 trans-activation to
demarcate the HOXB5-responsive element. It was found that
HOXB5 induced luciferase activity from D2 fragment (spanning
2932 to 2666) with heterologous SV40 promoter (Figure 2D; D2-
Luc). To directly confirm that HOXB5 enhances luciferase
expression by physical association with D2, EMSA and ChIP
analysis were performed in HOXB5 transfected SK-N-SH cells. D2
fragment was shown to bind to HOXB5 as revealed by EMSA. A
Protein-DNA complex was observed when nuclear extract or
HOXB5-GST fusion protein was incubated with biotin labeled D2
fragment probe (D2 probe), and this binding was abolished when
100-fold molar excess of cold probe was added (Figure 3A). ChIP
analysis was performed with an antibody to HOXB5; binding to D2
was detected by real-time quantitative PCR. Our result showed that
binding of HOXB5 to D2 was enriched compared to the non-
specific IgG control (Figure 3B). Furthermore, EMSA showed that
HOXB5 bind to the oligonucleotide D2A that contain the HOX
binding sequence (Figure 3C). HOXB5 was found neither associate
with nor trans-activate from the other PCR fragments (Figure S1).
HOXB5 synergizes NKX2-1 in RET transcription
Our group previously reported that NKX2-1 trans-activates the
RET promoter and is important for the expression of RET [13].
HOX binding site is located 874 nucleotides upstream of NKX2-1
binding site in the RET promoter, suggesting that these transcrip-
tion factors may cooperate in the regulation of RET transcription.
HOXB5 was co-transfected with NKX2-1 into SK-N-SH cells to
examine the cooperation between these two transcription factors in
the trans-activation of RET promoter. The inductions were
calculated as fold activations relative to the empty vector pRc/
CMV. HOXB5 showed a 7.3-fold induction, and NKX2-1
displayed a 4.5-fold induction from the RET promoter. In contrast,
14.5-fold induction was observed when HOXB5 and NKX2-1 were
co-transfected, which was significantly higher (p,0.05) than the
sum of trans-activation of HOXB5 and NKX2-1 alone (Figure 4A).
Binding of NKX2-1 to RET promoter is sensitive to the promoter
SNPs, which overlap the NKX2-1 binding site [13]. To examine if
the promoter SNPs affects the synergistic cooperation between
HOXB5 and NKX2-1, mutated full-length reporter constructs with
the two SNPs (-5G.A and -1A.C) or one SNP (-1A.C) were
examined for trans-activation by HOXB5 and NKX2-1. In line with
our previous findings, SNPs (-5G.A and -1A.C) and SNP (-1A.C)
reduced the trans-activation of RET promoter by NKX2-1
(Figure 4A). However, these SNPs did not affect the HOXB5
trans-activation. The synergistic cooperation of HOXB5 and NKX2-
1 in the trans-activation from the RET promoter was reduced
drastically by the SNPs. We further knockdown the endogenous
NKX2-1 expression in SK-N-SH by siRNA. Reduction of NKX2-1
expression by 7062% (mean6SD; p%0.005; n=3) (Figure 4B)
resulted in a significant reduction of HOXB5 trans-activation of RET
promoter by 68.767% (mean6SD; p=0.0003; n=3) (Figure 4C).
Synergistic interaction was not observed between HOXB5 and other
transcription factors PHOX2B, SOX10 and PAX3, that have been
shown capable of trans-activating RET promoter. Instead, only
additive effects were observed between HOXB5 and SOX10 in the
trans-activation of RET promoter (Figure S2).
The observation that HOXB5 and NKX2-1 bound to the RET
promoter, and HOXB5 synergized NKX2-1 in the RET
transcription, prompted us to investigate if HOXB5 physically
associates with NKX2-1. Using antiserum against HOXB5 for
pull-down and anti-NKX2-1 for the detection of NKX2-1 protein
Figure 1. HOXB5 trans-activates human RET gene. Trans-activation
activity of HOXB5 on RET promoter was assayed by measuring the
luciferase activity from human RET promoter luciferase reporter
construct. Luciferase activity was normalized with Renilla luciferase to
obtain relative luciferase unit. Data are shown as the fold increase
(mean6SD) in relative luciferase unit compared to that of pRC/CMV.
doi:10.1371/journal.pone.0020815.g001
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Figure 2. Localization of cis-regulatory element in RET promoter responsible for HOXB5 trans-activation. A, Schematic diagram of the
human RET promoter. ‘‘+1’’ denoted transcription start of RET gene, and the first ATG of RET gene was indicated. The 59 ends of sequential deletion
constructs of RET promoter were indicated with nucleotide positions. Location of the D2 element was indicated. B, Nucleotide sequence of the
human RET gene promoter was shown with the locations of various primers used for the generation of deletion constructs. Primers pair used for the
generation of D2 PCR fragment for EMSA, and for the PCR amplification in ChIP assays were indicated. The PCR primers (UD1 forward and reverse
primer) used for real-time quantitative PCR for the binding of D2 to HOXB5 were indicated with«. The D2A oligonucleotide probe (bold and italic)
which was specifically bound by HOXB5 as shown by EMSA was underlined with dotted arrow, and the putative HOXB5 binding site in D2 was
indicated by filled boxed. NKX2-1 binding site was boxed, and the two SNPs affecting NKX2-1 binding were indicated with downwards arrows.
Putative binding sites of other transcription factors were boxed and labeled accordingly. Abbreviations: TFIIB, transcription factor II B; SREBP, sterol
regulatory element-binding protein; MTE, human motif ten element. C, Trans-activation of HOXB5 on full-length and 59 deletion RET promoter was
HOXB5 Regulates RET Expression
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in the protein complex, NKX2-1 was co-precipitated with
HOXB5 in the Co-IP experiment (Figure 5A). As revealed by
ChIP analysis, the chromatin region containing D2 was precip-
itated with anti-HOXB5 and anti-NKX2.1 (Figure 5B). In
addition, binding of D2 to HOXB5 and NKX2-1 was further
confirmed by ChIP and quantitative PCR (Figure 5B). Taken
together all these suggested that HOXB5 and NKX2-1 formed a
protein complex and bound to the RET promoter.
Discussion
Expression and proper function of RET are crucial for the
development of ENS [3–6]. Loss-of-function mutations in RET
have been identified in both familial and sporadic cases of HSCR
[7,8,10]. Genetic variants in the cis-regulatory elements of RET
also play a role in mediating individual susceptibility to HSCR, by
compromising the RET expression [17,18]. Therefore, to unravel
the molecular mechanisms of the regulation of RET expression is
critical in understanding the molecular etiology of HSCR.
The minimal promoter (2177 to +196) of the human RET gene
contains regulatory elements for the binding of basal transcription
factors essential for basal RET expression [26–28]. On the other
hand, tissue-specific expression of RET is regulated by tissue-specific
transcription factors, working cooperatively via interactions with their
respective cis-regulatory elements in the RET promoter [15,16,25].
HOXB5 binds to the HOX consensus sequence at 875bp 59
upstream of transcription start of RET gene, and deletion of the
binding sequence abolishes HOXB5 trans-activation. HOXB5 and
NKX2-1 form protein complex binding to the RET promoter, and
work in a synergistic manner in mediating RET expression. Down-
regulation of NKX2-1 by siRNA suppresses HOXB5 trans-
activation of RET promoter, indicating that association with
NKX2-1 is essential for HOXB5 in the regulation of RET
expression. NKX2-1 binds at the region overlapping with the
transcription start site, and mediates RET transcription [13]. HSCR
associated SNPs at the NKX2-1 binding site (-5G.A rs10900296; -
1A.C rs10900297) reduce NKX2-1 binding and trans-activation
of RET [13,14,18,29–31]. These promoter SNPs have no direct
effect on HOXB5 trans-activation activity, but abolish the
synergistic interaction between HOXB5 and NKX2-1 on RET
transcription, indicating that binding of NKX2-1 to the promoter is
required for HOXB5 and NKX2-1 to work synergistically in
mediating RET expression. NKX2-1 is a developmentally regulated
homeodomain transcription factor [32], and possesses two tran-
Figure 3. HOXB5 physically associates with human RET promoter. A, EMSA assay with D2 and nuclear extract of HOXB5 transfected SK-N-SH
cells or purified GST-HOXB5 protein. Binding of D2 as indicated by retarded migration of D2 biotin probe (arrow) was specifically detected in lanes
with HOXB5 transfected SK-N-SH nuclear extract or purified HOXB5 protein. Addition of excess unlabeled D2 probe (D2 cold probe) either reduced or
completely abolished the binding of labeled D2 probe. B, ChIP was performed with HOXB5 transfected SK-N-SH cells, and binding of D2 to HOXB5
was determined by real-time quantitative PCR using UD1 forward and UD1 reverse primer. x-axis indicated fold enrichment normalized to the control
IgG. C, Binding of D2A oligonucleotide to purified HOXB5 protein as indicated by retarded migration of D2A probe. Addition of excess unlabeled D2A
probe reduced the binding markedly. No competition was observed with the addition of non-specific unlabled probe, and no binding was detected
with GST protein.
doi:10.1371/journal.pone.0020815.g003
assayed by measuring the luciferase activity from RET promoter luciferase reporter constructs. Luciferase activity was normalized with Renilla
luciferase to obtain relative luciferase unit. Percentage trans-activation of deletion constructs was determined by comparing luciferase activity to that
of full-length promoter construct, which was arbitrarily regarded as 100%. D, Trans-activation of HOXB5 from D2 was assayed by luciferase activity
from a D2-SV40 promoter luciferase reporter. Luciferase activity was normalized with Renilla luciferase to obtain relative luciferase unit. Fold increase
(mean6SD) was determined relative to luciferase unit of pRC/CMV which was arbitrarily regarded as 1.
doi:10.1371/journal.pone.0020815.g002
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scriptional activation domains that interacts with other proteins to
regulate target gene transcription [33]. We have previously
indentified a GlyRSer mutation in the NKX2-1 transcriptional
activation domain in one HSCR patient. This mutation (Gly322-
Ser) reduces the NKX2-1 induction of RET promoter without
affecting its binding onto the RET promoter, suggesting that the
GlyRSer mutation may interfere with the protein-protein interac-
tions of NKX2-1 with other transcription factors [14]. Further
experiments are needed to ascertain if HOXB5 interacts with
NKX2-1 via these transcriptional activator domains.
Our data show only an additive effect between HOXB5 and
SOX10 on the trans-activation from the full-length RET promoter
containing the SOX10/PAX3-responsive element. In line with a
lack of synergistic interactions between HOXB5 with SOX10 and
PAX3, HOXB5 exhibits comparable trans-activation from the
full-length promoter and truncated promoter (Del.D construct) in
which the SOX10/PAX3-responsive element is deleted. These
data indicate that HOXB5 mediates transcription of RET
independent of SOX10 or PAX3.
Although NCC express SOX10, PAX3, HOXB5, NKX2-1 and
RET, co-expression of these transcription factors and RET is not
always found in all SOX10-, PAX3- or HOXB5-expressing tissues
[15,19,34]. Furthermore, SK-N-SH cells express RET and NKX2-1,
but not SOX10, PAX3 and HOXB5 [25] (Figure S3). Using dual
Figure 4. HOXB5 synergizes NKX2-1 in trans-activation of human RET gene. A, Wild-type or mutated (SNPs -5G.A and -1A.C) or (-1A.C)
full-length RET promoter was transfected with HOXB5 or NKX2-1 alone or in combination into SK-N-SH cells. Relative luciferase units for each
combinations were determined, and fold increase (mean6SD) was calculated as compared to luciferase unit of empty vector (pXP1 Basic), which was
arbitrarily regarded as 1. B, Expression levels of NKX2-1 mRNA were determined by real-time RT-PCR quantitation in non-transfected SH-N-SH cell and
SH-N-SH cell transfected with NKX2-1 siRNA or negative control siRNA (Ctrl siRNA). Relative expressions of NKX2-1 were calculated with reference to
non-transfected cell, which was arbitrarily regarded as 100%. C, full-length RET promoter was transfected with HOXB5 alone or in combination with
NKX2-1 siRNA or negative control siRNA (Ctrl siRNA). Relative luciferase units for each combination were determined, and fold increase (mean6SD)
was calculated as compared to luciferase unit of empty vector (pRC/CMV), which was arbitrarily regarded as 1.
doi:10.1371/journal.pone.0020815.g004
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luciferase-reporter assays, we have previously shown that NKX2-1
indeed works coordinately with PHOX2B and SOX10, but not
PAX3, to mediate RET transcription [25]. It would appear that the
expression of RET is regulated by a number of transcription factors
including HOXB5, NKX2-1, SOX10, PAX3 and PHOX2B, and
that none of these transcription factors is necessary or sufficient for
RET transcription. Instead, these transcription factors work either in
a synergistic and/or additive manner to mediate RET expression.
RET is repressed in most tissues and cells, and its expression is
associated with a transition from a repressive chromatin to an open,
permissive chromatin [35,36]. It is plausible to speculate that
association of HOXB5 with HOX binding sequence and interaction
with NKX2-1 at the transcription start site, may induce conforma-
tional change of the RET promoter bringing transcription factors in
close proximity of minimal promoter facilitating the recruitment of
basal transcription factors mediating RET transcription.
In conclusion, we showed that i) HOXB5 binds to crucial RET
regulatory region and affects RET expression; ii) HOXB5
synergizes with NKX2-1 transcription factor, and iii) HOXB5
regulatory activity is compromised by sequence variants within
RET regulatory regions. Taken altogether, our data suggests that
HOXB5,in coordination with NKX2-1, plays an essential role in
RET expression. Future studies shall focus in delineating the
interplay of molecular components implicated in the regulation of
RET expression, which will provide important mechanistic insights
into the pathogenesis of HSCR.
Materials and Methods
Cell culture
Human neuroblastoma cell line SK-N-SH (#HTB-11) (ATCC,
Manassas, USA) was cultured in Eagle’s minimal essential medium
(EMEM) (ATCC, Manassas, USA) supplemented with 10% fetal
bovine serum (FBS) (Gibco, Invitrogen, Carlsbad, USA) without
antibiotics at 37uC and 5% CO2. Trypsin-EDTA solution (0.25%;
w/v) was used for trypsinization of cells. Cells were stored in 5%
(v/v) DMSO in liquid nitrogen.
Luciferase-reporter constructs
The 3.7 kb RET full-length promoter (1545 to 5270, AF032124,
Genbank), the 372 bp minimal promoter and the mutated RET
full-length promoter containing -5G.A and -1A.C or -1A.C
alleles, were generated by PCR and cloned upstream of the
luciferase reporter in the pXP1 vector (AF093683, GenBank) [13].
All of these constructs contain a 195 bp 59UTR of RET gene. A
1.4 kb 59 deletion construct (Del.D), was generated by cloning of
the PCR fragment (-1205 to 195) of RET gene upstream of the
luciferase reporter in the pXP1 vector. Furthermore, D2A-Luc
construct was generated by cloning of the PCR fragment (-932 to -
666) of RET gene upstream of the luciferase reporter in the pGL3
vector (Promega, Madison, USA).
Transient transfection and dual-luciferase reporter assay
SK-N-SH cells were seeded on 24-well 18 hours prior to
transfection. Cells were co-transfected with pRL internal
control, reporter constructs and appropriate amount HOXB5
and/or NKX2-1 expression vectors with Lipofectamine 2000
(Invitrogen, Carlsbad, USA). Cell lysate was analyzed 24 hours
by Dual-Luciferase Reporter Assay System (Promega, Madison,
USA) on MicroLumatPlus LB 96V instrument. At least two
independent triplicate or quintupled experiments were per-
formed, and the luciferase activity was presented as relative
luciferase unit (RLU) normalized with the Renilla luciferase
internal control.
Figure 5. HOXB5 and NKX2-1 form a protein complex binding to RET promoter. A, Immuno-precipitation (IP) on nuclear extract of HOXB5
transfected SK-N-SH cells with aHOXB5 antibody. Protein complexes precipitated with aHOXB5 or non-specific IgG were resolved by SDS-PAGE, and
NKX2-1 in the complex was detected by immuno-blotting using aNKX2-1 antibody. NKX2-1 (38KD) was specifically detected in the lane of protein
complex precipitated with aHOXB5. B, Chromatin immuno-precipitation (ChIP) of HOXB5 transfected SK-N-SH cells and aHOXB5 or aNKX2-1 antibody.
D2 was amplified from chromatin precipitated with aHOXB5, and aNKX2-1, but not in the preparation with non-specific IgGs (mIG; rIG). Bindings of
HOXB5 and NKX2-1 to D2 were detected by real-time quantitative PCR. x axis is fold enrichment normalized to the non-immune mouse IgG control.
doi:10.1371/journal.pone.0020815.g005
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Small interference RNA knockdown of NKX2-1
Transfection of small interfering RNA (siRNA) was performed
using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, USA)
according to the siRNA-plasmid co-transfection protocol from
Invitrogen. Human NKX2-1 siRNA (Stealth RNAi HSS144278)
and negative control (Stealth RNAi 12935-200) were purchased
from Invitrogen (Invitrogen, Carlsbad, USA).
Real-time PCR
Real-time PCR was performed on 7900HT Fast Real-Time
PCR System (Applied Biosystems, Foster City, USA) using Fast
SYBR Green Master Mix (Applied Biosystems, Foster City, USA)
according to the manufacturer’s protocol.
Co-immunoprecipitation
Nuclear protein from NKX2-1/HOXB5 co-transfected SK-N-
SH cells was prepared by NE-PER Nuclear and Cytoplasmic
Extraction Reagent (Pierce Thermo Fisher, Rockford, USA), and
pre-cleared with 50%-slurry of Protein G-Agarose. After pre-
clearing, the slurry was incubated with mouse anti-HOXB5
antibody (133C3a, 25 mg; Santa Cruz, Santa Cruz, USA) or non-
immunized mouse IgG control (5 mg; Santa Cruz, Santa Cruz,
USA) at 4uC for 3 hours. The immune-precipitated protein
complexes were resolved in a 8% SDS-Polyacrylamide gel before
electro-transferred onto PVDF membrane. Mouse anti-NKX2-1
primary antibody (F-12, 1:1,000; Santa Cruz, Santa Cruz, USA)
and goat anti-mouse HRP-conjugated secondary antibody
(Zymed, San Francisco, USA) were used in western blot detection.
Signals were visualized by chemiluminescence using ECL Plus
Western Blotting Detection Kit (GE Healthcare).
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extract from HOXB5 transfected SH-N-SH cells and
HOXB5-GST fusion protein (Abnova, Taipei, Taiwan) were used
in this study. End-to-end overlapping PCR fragments (generated
using primers as shown in Table 1) spanning the D2 region of RET
were labeled with Biotin-11-UTP (Pierce, Thermo Fisher, Rock-
ford, USA). In brief, 25 fmole of Biotin-labeled DNA fragment was
incubated with nuclear extract (7 mg) or HOXB5-GST protein
(0.25 mg) with or without the addition of unlabeled fragment as
specific competitor (300-fold in excess) in binding buffer (Lightshift
Chemiluminescent EMSA Kit Pierce, Thermo Fisher, Rockford,
USA) at room temperature for 25 minutes. Protein-DNA complex
was resolved by electrophoresis on a 4.5% non-denaturing
polyacrylamide gel, before being electro-transferred onto PVDF
membrane, and signals were detected by chemiluminescence.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using
MAGnifyTM ChIP System (Invitrogen, Carlsbad, USA) according
to the manufacturer’s instruction. Briefly, 36106 HOXB5/NKX2-1
transfected SK-N-SH cells were cross-linked in 1% formaldehyde
and chromatin DNA was sheared by sonication (Vibra-cell
VCX750 sonicator; 35% amplification, 20s ON plus 40s OFF,
25 cycles) to generate fragments of around 500 bp in length.
DynabeadsH were pre-coupled with anti-HOXB5 (133c3a, Santa
Cruz), anti-NKX2-1 (H-190, Santa Cruz), mouse or rabbit IgG.
Sheared chromatin DNA was incubated with corresponding
antibody-coupled beads at 4uC with rotation for 3 hours. After
pull-down and reversion of cross-linking, chromatin DNA was
purified. Binding of D2 to HOXB5 and NKX2-1 was quantified
by real-time quantitative PCR analysis.
Supporting Information
Figure S1 A, Schematic diagram of the human RET
promoter. ‘‘+1’’ denoted transcription start of RET gene, and
the first ATG of RET gene was indicated. B, Overlapping DNA
fragments (D1 to D4) were generated by PCR and labeled with
biotin for EMSA. Only D2 was able to bind to HOXB5 as shown
by the retarded migration of the probe (arrow). C, Trans-
activation of HOXB5 from D1 to D4 fragments were assayed by
luciferase activity. Luciferase activity was normalized with Renilla
luciferase to obtain relative luciferase unit. Fold increase
(mean6SD) was determined relative to luciferase unit of empty
vector (SV40-LUC) which was arbitrarily regarded as 1.
(TIF)
Figure S2 No synergistic interaction between HOXB5
and PHOX2B, SOX10 or PAX3 in the trans-activation of
RET promoter. Wild-type full-length RET promoter was
transfected with expression constructs of HOXB5, SOX10,
PAX3 and PHOX2B either alone or in combination into SK-N-
SH cells. Relative luciferase units for each combinations were
determined, and fold increase (mean6SD) was calculated as
Table 1. Primers for PCR amplification.
Amplification Primers Annealing Temperature
Del.D (-1205 to 195) Forward: 59- TCCTGCCTGTGAGGGTGAC-39 61uC
Reverse: 59- AGTTGCTCTCCAGCGGTTC-39
D1 (-1205 to -912) Forward: 59-TCCTGCCTGTGAGGGTGAC-39 62uC
Reverse: 59-GGGTGAGGTTGGATGTGGG-39
D2 (-932 to -666) Forward: 59-AGCCCACATCCAACCTCACC-39 62uC
Reverse: 59-CCTCCAGCACTGGTCCAACC-39
D3 (-700 to -363) Forward: 59-TTTCCGGTTTCCAAGGGTTG-39 62uC
Reverse: 59-CCTGCCTTTTGCCCTTTCC-39
D4 (-387 to -115) Forward: 59-TGCAGCGGAAAGGGCAAAAG-39 62uC
Reverse: 59-CGCGTGTAGGAGCTCAGTG-39
D2A (-932 to -666) Forward: 59-AGCCCACATCCAACCTC-39 61uC
Reverse: 59-CCTCCAGCACTGGTCC-39
doi:10.1371/journal.pone.0020815.t001
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compared to luciferase unit of empty vector (pXP1 Basic), which
was arbitrarily regarded as 1.
(TIF)
Figure S3 SK-N-SH cells express RET and NKX2-1, but
not SOX10, PAX3 and HOXB5. Total RNA was isolated from
SK-N-SH cells for RT-PCR analysis to assay for the expression of
RET, NKX2-1, SOX10, PAX3 and HOXB5. RT-PCR for b-actin
was included as a positive control to test the integrity of the RNA
and the RT-PCR reaction. PCR products were separated by
agarose gel electrophoresis and visualized by ethidium bromide
staining.
(TIF)
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